Thibault Mesplede
Overview
Explore the profile of Thibault Mesplede including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Kampen J, van Nood E, Mahmud R, Krullaars Z, Voskamp T, Voskamp M, et al.
Open Forum Infect Dis
. 2025 Jan;
12(1):ofae705.
PMID: 39741997
Background: The treatment management of human immunodeficiency virus (HIV)-2 infection presents greater challenges compared to HIV-1 infection, primarily because of inherent resistance against non-nucleoside reverse transcriptase inhibitors. Integrase strand transfer...
2.
Rodriguez-Lopez E, Lopez P, Rodriguez Y, Sanchez R, Acevedo V, Encarnacion J, et al.
AIDS Res Hum Retroviruses
. 2024 Aug;
41(1):43-54.
PMID: 39086253
The recently Food and Drug Administration (FDA)-approved cabotegravir (CAB) has demonstrated efficacy as an antiretroviral agent for HIV treatment and prevention, becoming an important tool to stop the epidemic in...
3.
Mesplede T, Gantner P
Clin Infect Dis
. 2024 Mar;
79(6):1541-1542.
PMID: 38462992
No abstract available.
4.
Ursenbach A, Ruch Y, Hoellinger B, Fuchs A, Caspar S, Jegou F, et al.
Clin Infect Dis
. 2024 Jan;
79(1):198-201.
PMID: 38193816
Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by...
5.
Lungu C, Overmars R, Grundeken E, Boers P, van der Ende M, Mesplede T, et al.
Viruses
. 2023 Nov;
15(11).
PMID: 38005913
Although some individuals with HIV-2 develop severe immunodeficiency and AIDS-related complications, most may never progress to AIDS. Replication-competent HIV-2 isolated from asymptomatic long-term non-progressors (controllers) have lower replication rates than...
6.
Xiao M, Cleyle J, Yoo S, Forrest M, Krullaars Z, Pham H, et al.
Antimicrob Agents Chemother
. 2023 Apr;
67(5):e0138622.
PMID: 37071019
Human immunodeficiency virus (HIV) treatment with antiretroviral regimens containing integrase strand transfer inhibitors such as dolutegravir (DTG) and bictegravir (BIC) offers high levels of protection against the development of drug...
7.
Prins H, Crespo R, Lungu C, Rao S, Li L, Overmars R, et al.
Sci Adv
. 2023 Mar;
9(11):eade6675.
PMID: 36921041
Reactivation of the latent HIV-1 reservoir is a first step toward triggering reservoir decay. Here, we investigated the impact of the BAF complex inhibitor pyrimethamine on the reservoir of people...
8.
Overmars R, Krullaars Z, Mesplede T
Expert Opin Investig Drugs
. 2023 Feb;
32(2):127-139.
PMID: 36751107
Introduction: Since the first antiretroviral drug was described, the field of HIV treatment and prevention has undergone two drug-based revolutions: the first one, enabled by the virtually concomitant discovery of...
9.
van Kampen J, Pham H, Yoo S, Overmars R, Lungu C, Mahmud R, et al.
J Glob Antimicrob Resist
. 2022 Nov;
31:323-327.
PMID: 36347497
Objectives: We report a case of incomplete HIV-1 suppression on a dolutegravir, lamivudine, and abacavir single-tablet regimen with the emergence of the H51Y and G118R integrase resistance mutations. Methods: Integrase...
10.
Ohnona F, Moisi D, Ibanescu I, Mesplede T, Brenner B, Wainberg M
Virologie (Montrouge)
. 2021 Aug;
15(6):395-400.
PMID: 34428870
As part of a program for HIV-1 detection in the gay community of Montreal, blood sampling on "FTA Classic" papers (DBS "dried blood spot") has been tested and validated. It...